Olorinab
- Generic Name
- Olorinab
- Drug Type
- Small Molecule
- Chemical Formula
- C18H23N5O3
- CAS Number
- 1268881-20-4
- Unique Ingredient Identifier
- 581F7DFA9B
- Background
Olorinab is under investigation in clinical trial NCT03155945 (Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain).
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT04655599
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 273
- Registration Number
- NCT04043455
- Locations
- 🇺🇸
WR-ClinSearch, LLC, Chattanooga, Tennessee, United States
🇺🇸Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸New River Valley Research Institute, Christiansburg, Virginia, United States
Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT03155945
- Locations
- 🇺🇸
University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath